{"entity":{"id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","aka":[],"tldr":"A phase 3 trial of Furmonertinib, Carboplatin, Cisplatin, Pemetrexed and Osimertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.","summary":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases is a phase 3 interventional study registered as NCT06970639 by Allist Pharmaceuticals, Inc., with 380 participants planned, started 2024-09-26 and due to reach its primary completion in 2029-03. Interventions recorded: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection and Osimertinib Mesylate Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06970639","url":"https://clinicaltrials.gov/study/NCT06970639"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["furmonertinib","carboplatin","cisplatin","pemetrexed","osimertinib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06970639","phase":"3","setting":"A Phase III, International, Multicenter, Randomized, Controlled, Open-label Clinical Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","sponsor":"Allist Pharmaceuticals, Inc.","enrolled":380,"outcomes":[]},"route":"/trials/nct06970639/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}]}}